| Adjuvant docetaxel for node-positive breast cancer. BCIRG Investigators. New England Journal of Medicine 352 (22), 2302-13, 2005 | 1343 | 2005 |
| Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial E Abraham, K Reinhart, S Opal, I Demeyer, C Doig, AL Rodriguez, ... Jama 290 (2), 238-247, 2003 | 1255 | 2003 |
| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ... The lancet oncology 18 (12), 1688-1700, 2017 | 640 | 2017 |
| PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers RRL Bastien, Á Rodríguez-Lescure, MTW Ebbert, A Prat, B Munárriz, ... BMC medical genomics 5, 1-12, 2012 | 396 | 2012 |
| The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER) M Aapro, A Molassiotis, M Dicato, I Peláez, Á Rodríguez-Lescure, ... Annals of oncology 23 (8), 1986-1992, 2012 | 354 | 2012 |
| Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer M Martín, Á Rodríguez-Lescure, A Ruiz, E Alba, L Calvo, M Ruiz-Borrego, ... Journal of the National Cancer Institute 100 (11), 805-814, 2008 | 295 | 2008 |
| Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and … M Martin, A Lluch, MA Segui, A Ruiz, M Ramos, E Adrover, ... Annals of oncology 17 (8), 1205-1212, 2006 | 261 | 2006 |
| Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial JR Mackey, M Martin, T Pienkowski, J Rolski, JP Guastalla, A Sami, ... The Lancet Oncology 14 (1), 72-80, 2013 | 260 | 2013 |
| Defining breast cancer intrinsic subtypes by quantitative receptor expression MCU Cheang, M Martin, TO Nielsen, A Prat, D Voduc, ... The oncologist 20 (5), 474-482, 2015 | 258 | 2015 |
| Adjuvant docetaxel for high-risk, node-negative breast cancer M Martín, MA Seguí, A Antón, A Ruiz, M Ramos, E Adrover, I Aranda, ... New England Journal of Medicine 363 (23), 2200-2210, 2010 | 251 | 2010 |
| Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2− breast cancer patients: results from the GEICAM 9906 trial M Martin, JC Brase, L Calvo, K Krappmann, M Ruiz-Borrego, K Fisch, ... Breast Cancer Research 16, 1-11, 2014 | 181 | 2014 |
| Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer CE Geyer Jr, JE Garber, RD Gelber, G Yothers, M Taboada, L Ross, ... Annals of oncology 33 (12), 1250-1268, 2022 | 162 | 2022 |
| Predicting response and survival in chemotherapy-treated triple-negative breast cancer A Prat, A Lluch, J Albanell, WT Barry, C Fan, JI Chacón, JS Parker, ... British journal of cancer 111 (8), 1532-1541, 2014 | 149 | 2014 |
| PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer M Martín, A Prat, Á Rodríguez-Lescure, R Caballero, MTW Ebbert, ... Breast cancer research and treatment 138, 457-466, 2013 | 126 | 2013 |
| Phase III trial of adjuvant capecitabine after standard neo-/adjuvant chemotherapy in patients with early triple-negative breast cancer (GEICAM/2003-11_CIBOMA/2004-01) A Lluch, CH Barrios, L Torrecillas, M Ruiz-Borrego, J Bines, J Segalla, ... Journal of clinical oncology 38 (3), 203-213, 2020 | 115 | 2020 |
| Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer M Martín, Á Rodríguez-Lescure, A Ruiz, E Alba, L Calvo, M Ruiz-Borrego, ... Breast cancer research and treatment 123, 149-157, 2010 | 113 | 2010 |
| Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis B Pajares, M Pollán, M Martín, JR Mackey, A Lluch, J Gavila, C Vogel, ... Breast Cancer Research 15, 1-14, 2013 | 96 | 2013 |
| Epirubicin–cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive … C Pico, M Martin, C Jara, A Barnadas, A Pelegri, A Balil, C Camps, A Frau, ... Annals of Oncology 15 (1), 79-87, 2004 | 96 | 2004 |
| Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study E Alba, M Ruiz-Borrego, M Margelí, Á Rodríguez-Lescure, ... Breast cancer research and treatment 122, 169-176, 2010 | 93 | 2010 |
| Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers JAG Agúndex, M Olivera, JM Ladero, A Rodriguez-Lescure, MC Ledesma, ... Pharmacogenetics and Genomics 6 (6), 501-512, 1996 | 87 | 1996 |
